Michael F Daily, MD

Bio / Education: 

Medical School
University of Utah School of Medicine, Salt Lake City

Residency
University of Utah School of Medicine, Salt Lake City

Fellowship
Thomas Starzl Transplant Institute
University of Pittsburgh Medical Center, Pittsburgh, PA

Licensure
2001 – Present: State of Utah
2005 – Present: State of Pennsylvania
2007 – Present: State of California

Board Certification
2001 - National Board of Medical Examiners
2000 - Present: Advanced Cardiac Life Support
2001 - Present: Advanced Trauma Life Support
2006 - American Board of Surgery

Surgical Interests
Hepatobiliary and renal transplantation

PubMed Publications: 

  • Kim, S.;Maynard, E.C.;Shah, M.B.;Daily, M.F.;Tzeng, C.W.;Davenport, D.L.;Gedaly, R. "Risk Factors for 30-day Readmissions after Hepatectomy: Analysis of 2444 Patients from the ACS-NSQIP Database." Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract (2014): [PubMed Link] | [ Full text ]
  • Galuppo, R.;Maynard, E.;Shah, M.;Daily, M.F.;Chen, C.;Spear, B.T.;Gedaly, R. "Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways." Anticancer research 34, 4 (2014): 1709-13. [PubMed Link] | [ Full text ]
  • Gedaly, R.;Galuppo, R.;Daily, M.F.;Shah, M.;Maynard, E.;Chen, C.;Zhang, X.;Esser, K.A.;Cohen, D.A.;Evers, B.M.;Jiang, J.;Spear, B.T. "Targeting the Wnt/β-catenin signaling pathway in liver cancer stem cells and hepatocellular carcinoma cell lines with FH535." PloS one 9, 6 (2014): e99272. [PubMed Link] | [ Full text ]
  • Gedaly, R.;Galuppo, R.;Musgrave, Y.;Angulo, P.;Hundley, J.;Shah, M.;Daily, M.F.;Chen, C.;Cohen, D.A.;Spear, B.T.;Evers, B.M. "PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation." The Journal of surgical research 185, 1 (2013): 225-30. [PubMed Link] | [ Full text ]
  • Gedaly, R.;Angulo, P.;Chen, C.;Creasy, K.T.;Spear, B.T.;Hundley, J.;Daily, M.F.;Shah, M.;Evers, B.M. "The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment." Anticancer research 32, 7 (2012): 2531-6. [PubMed Link] | [ Full text ]
  • Moreno Elola-Olaso, A.;Davenport, D.L.;Hundley, J.C.;Daily, M.F.;Gedaly, R. "Predictors of surgical site infection after liver resection: a multicentre analysis using National Surgical Quality Improvement Program data." HPB : the official journal of the International Hepato Pancreato Biliary Association 14, 2 (2012): 136-41. [PubMed Link] | [ Full text ]
  • Gedaly, R.;Angulo, P.;Hundley, J.;Daily, M.F.;Chen, C.;Evers, B.M. "PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation." The Journal of surgical research 176, 2 (2012): 542-8. [PubMed Link] | [ Full text ]
  • Gedaly, R.;Daily, M.F.;Davenport, D.;McHugh, P.P.;Koch, A.;Angulo, P.;Hundley, J.C. "Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database." Archives of surgery (Chicago, Ill. : 1960) 146, 8 (2011): 953-8. [PubMed Link] | [ Full text ]
  • Gedaly, R.;Angulo, P.;Hundley, J.;Daily, M.F.;Chen, C.;Koch, A.;Evers, B.M. "PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways." Anticancer research 30, 12 (2010): 4951-8. [PubMed Link] | [ Full text ]
X
Enter your College of Medicine username.
Enter the password that accompanies your username.
Loading